A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis

This is an interventional treatment trial for Osteoarthritis, Hip focused on measuring platelet-rich plasma, leukocyte poor platelet rich plasma, PRP, hip osteoarthritis, osteoarthritis, Regenerative orthopedics and sports medicine, ROSM, EmCyte Read More

Inclusion:

1. Symptomatic OA of hip (K-L Grade 1-3) documented by x-ray taken within the past 6 months
2. Male or female age 30 - 65 at time of enrollment
3. Patients must have adequate immune system function with no known immunodeficiency
4. disease
5. Has not had a corticosteroid injection in the past 6 months
6. Has not used non-steroidal anti-inflammatory 7 days prior to treatment and has not used oral
7. corticosteroids 30 days prior to treatment
8. If on chronic anticoagulant medication, we will follow the recommendations of the physician
9. managing their anticoagulant medication
10. Willing and able to participate for the entire study period
11. No evidence of current systemic infection or illness (eg. fever, malaise, etc.) and no evidence
12. of skin infection in the areas where the injection will be performed

Exclusion:

1. Patients have been diagnosed with an autoimmune disease, diabetes, rheumatoid arthritis,
2. hematologic conditions predisposing to bleeding disorders or platelet dysfunction, Paget's disease of femur or ilium, avascular necrosis (AVN) of the femoral head, infectious arthritis, Lyme disease.
3. Previous reparative cellular/ orthobiologics /PRP injection
4. ≥7mm hip effusion as measured on ultrasound at the femoral neck
5. K-L Grade 4 OA x-ray documented
6. Patient has a history of alcohol or drug abuse within the six months prior to enrolment in the study
7. Patients who had intra-articular treatment with corticosteroids within 6 months of randomization in this study
8. Patient received more than 2 previous intra- or extra-articular corticosteroid injections to the affected hip.
9. Patients who are pregnant or nursing at the time of consent
10. Patients who have had anorexia, chronic insomnia, immunocompromised state, and/ or are on immunosuppressive medication
11. Neoplastic cancer within 5 years prior to screening and no evidence of recurrence, except for cutaneous (basal cell and squamous cell) cancer treated with excision
12. History of chemotherapy within the past 3 years or radiation therapy to the involved hip area
13. Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)
14. Patients who have had previous intervention to the hip except for labral repair/ reconstruction and/ or femoral neck osteoplasty or acetabular osteoplasty without microfracture.
15. Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.
16. Use of NSAID 7 days prior to treatment or oral or subcutaneous corticosteroids 30 days prior
17. Patients with a BMI over 35
18. Deformity or dysplasia (i.e. Legg Calve Perthes or DDH) other than FAI.
19. Patients with systemic infection, hematological conditions, malignancy, blood borne diseases, allergies to lidocaine.